News | March 14, 2023
Alpla and Inden pharma form joint venture
ALPLA is expanding its presence in the global market for pharmaceutical packaging by establishing a joint venture with Inden Pharma
ALPLA is expanding its presence in the global market for pharmaceutical packaging by establishing a joint venture with Inden Pharma
The acquisition continues the growth and expansion course of the ALPLApharma business division established in 2019
Efgartigimod is approved in the United States as VYVGART for the treatment of adults with generalized myasthenia gravis
In the UK, Bartec has been synonymous with Mediso products for 18 years, proof of a successful partnership
The company plans to file its NDA in China and MAA in the EU in 2022, making Hansizhuang potentially to be the world's first PD-1 inhibitor for the first-line treatment of SCLC
Ritonavir oral tablet is a pharmacokinetic booster of multiple oral antiviral drugs targeting viral proteases and a component of the approved oral antiviral drug Paxlovid (Nirmatrelvir 300 mg tablet + ritonavir 100 mg tablet co-administration package)
Launches a host of innovative products & solutions across the entire flexible packaging value chain in October - December 2021
The recommended daily dose for Ryaltris is 2 sprays in each nostril twice daily
Celltrion plans to provide dual treatment options for COVID-19; Regkirona for hospitalised patients and a nebulised cocktail therapy (CT-P63 in combination with Regkirona) for at- home settings
Ryaltris is a fixed dose combination nasal spray that combines an antihistamine (Olopatadine) with a steroid (Mometasone Furoate) for treatment of allergic rhinitis
Subscribe To Our Newsletter & Stay Updated
